Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Gastrointestinal Therapeutics in Asia-Pacific Market – Introduction
2.1 Irritable Bowel Syndrome
2.1.1 Classification
2.1.2 Symptoms
2.1.3 Etiology
2.1.4 Pathophysiology
2.1.5 Diagnosis
2.1.6 Epidemiology
2.1.7 Prognosis
2.1.8 Treatment Options
2.2 Ulcerative Colitis
2.2.1 Classification
2.2.2 Symptoms
2.2.3 Etiology
2.2.4 Pathophysiology
2.2.5 Diagnosis
2.2.6 Epidemiology
2.2.7 Prognosis
2.2.8 Treatment Options
2.3 Crohn’s Disease
2.3.1 Classification
2.3.2 Symptoms
2.3.3 Etiology
2.3.4 Pathophysiology
2.3.5 Diagnosis
2.3.6 Epidemiology
2.3.7 Prognosis
2.3.8 Treatment Options
2.4 GBI Research Report Guidance
3 Gastrointestinal Therapeutics in Asia-Pacific Market – Marketed Products (Global)
3.1 Irritable Bowel Syndrome
3.2 Ulcerative Colitis
3.3 Crohn’s Disease
3.4 Key Marketed Products
3.4.1 Amitiza
3.4.2 Humira
3.4.3 Remicade
3.4.4 Simponi
3.4.5 Cimzia
3.4.6 Tysabri
4 Gastrointestinal Therapeutics in Asia-Pacific Market – Pipeline Analysis
4.1 Irritable Bowel Syndrome
4.1.1 Overall Pipeline
4.1.2 Pipeline Analysis by Molecule Type
4.1.3 Pipeline Analysis by Mechanism of Action
4.2 Ulcerative Colitis Pipeline
4.2.1 Overall Pipeline
4.2.2 Pipeline Analysis by Molecule Type
4.2.3 Pipeline Analysis by Mechanism of Action
4.2.4 Crohn’s Disease Pipeline
4.2.5 Overall Pipeline
4.2.6 Pipeline Analysis by Molecule Type
4.2.7 Pipeline Analysis by Mechanism of Action
4.3 Promising Drug Candidates in the Pipeline
4.3.1 GSK-1605786
4.3.2 MLN0002
4.3.3 EMD-61753
5 Gastrointestinal Therapeutics in Asia-Pacific Market – Market Forecast to 2019
5.1 Asia-Pacific Markets
5.1.1 Treatment Usage Patterns
5.1.2 Annual Cost of Therapy
5.1.3 Market Size
5.2 Australia
5.2.1 Treatment Usage Patterns
5.2.2 Annual Cost of Therapy
5.2.3 Market Size
5.3 India
5.3.1 Treatment Usage Patterns
5.3.2 Annual Cost of Therapy
5.3.3 Market Size
5.4 China
5.4.1 Treatment Usage Patterns
5.4.2 Annual Cost of Therapy
5.4.3 Market Size
5.5 Japan
5.5.1 Treatment Usage Patterns
5.5.2 Annual Cost of Therapy
5.5.3 Market Size
5.6 Drivers and Barriers
5.6.1 Drivers
5.6.2 Barriers
6 Gastrointestinal Therapeutics in Asia-Pacific Market – Deals and Strategic Consolidations (Global)
6.1 Deals Analysis
6.2 Major Co-Development Deals
6.2.1 AstraZeneca Enters into Co-Development Agreement with Ironwood Pharma for Linaclotide
6.2.2 Amgen Enters into Co-development Agreement with AstraZeneca for Five Monoclonal Antibodies
6.2.3 Galapagos and AbbVie Extend GLPG0634 Development Agreement to Include Crohn's Disease
6.3 Major Licensing Deals
6.3.1 AstraZeneca Enters into Licensing Agreement with Ardelyx for NHE3 Inhibitor Program
6.3.2 Sanofi-Aventis Enters into Licensing Agreement with Kyowa Hakko Kirin
6.3.3 GlaxoSmithKline Enters into Licensing Agreement with ChemoCentryx
7 Gastrointestinal Therapeutics in Asia-Pacific Market – Appendix
7.1 Market Definitions
7.2 Abbreviations
7.3 Sources
7.4 All Pipeline Drugs by Phase
7.4.1 Discovery
7.4.2 Preclinical
7.4.3 IND/CTA-filed
7.4.4 Phase I
7.4.5 Phase II
7.4.6 Phase III
7.4.7 Pre-Registration
7.4.8 Undisclosed
7.5 Market Forecasts to 2019
7.5.1 Asia-Pacific Markets
7.5.2 Australia
7.5.3 India
7.5.4 China
7.5.5 Japan
7.6 Research Methodology
7.6.1 Coverage
7.6.2 Secondary Research
7.6.3 Primary Research
7.6.4 Therapeutic Landscape
7.6.5 Geographical Landscape
7.6.6 Pipeline Analysis
7.7 Expert Panel Validation
7.8 Contact Us
7.9 Disclaimer